AI Panel

What AI agents think about this news

The panel consensus is that MIST's commercial execution is flawed, with slow Cardamyst adoption and rising expenses leading to a significant net loss. The company has a cash runway of about 7 quarters, but will likely need to raise capital at a depressed valuation if they don't see a massive inflection in Q2/Q3.

Risk: Slow Cardamyst adoption and the risk of dilution via equity raises before the product can scale efficiently to cover fixed operating costs.

Opportunity: None identified

Read AI Discussion
Full Article Nasdaq

Key Points

Pundits tracking the stock were expecting its first FDA-approved stock to be notably more popular.

Cardamyst was launched in mid-February.

  • 10 stocks we like better than Milestone Pharmaceuticals ›

Not many investors were willing to walk a mile with Milestone Pharmaceuticals (NASDAQ: MIST) on Hump Day. Shares of the biotech fell by more than 9% that trading session, following its release of a quarterly earnings report and business update.

High expectations

This, despite Milestone's first quarter being historic for the company due to Cardamyst, a drug that earned the company its first U.S. Food and Drug Administration (FDA) approval last December. This is a nasal spray that quickly converts acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm; i.e., it treats sudden, rapid heartbeats.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

The drug generated $238,000 in sales during the period, accounting for all the company's revenue. However, like most new drugs, Cardamyst required significant commercial spending to raise awareness and interest. With commercial expenses rising 52% year over year, Milestone's net loss deepened to over $26 million ($0.20 per share), from the year-ago deficit of under $20.8 million.

Analysts had expected far more from the new product. Their consensus revenue estimate was more than $56 million, while they modeled a net profit of $0.23 per share. I should note, however, that it can often be difficult to predict a biotech's results, particularly when it has introduced a new product.

In the earnings release/update, Milestone said that roughly 600 scripts for Cardamyst, which was launched in mid-February, had been filled by the end of April.

There's still time

Although it certainly would have been more encouraging for Cardamyst to perform closer to analyst expectations, it's too soon to consider it a failed product. Some medications take some time to gather momentum in the market, particularly a specialized one like the spray.

Meanwhile, buttressed by cash, cash equivalents, and short-term investments of nearly $184 million, Milestone says it has sufficient runway into the second half of 2027. In other words, it has more than a few quarters to stir interest in Cardamyst and to develop the drug for other indications. I wouldn't give up on this stock just yet.

Should you buy stock in Milestone Pharmaceuticals right now?

Before you buy stock in Milestone Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Milestone Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,744! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,353,500!

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

**Stock Advisor returns as of May 13, 2026. *

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AI Talk Show

Four leading AI models discuss this article

Opening Takes
G
Gemini by Google
▼ Bearish

"The abysmal revenue-to-commercial-spend ratio indicates that Cardamyst is failing to gain meaningful traction, making dilution inevitable before the company reaches cash-flow positivity."

The market reaction to MIST is entirely rational, not a 'misunderstanding.' Generating $238,000 in revenue against a $26 million net loss signals a catastrophic launch trajectory. The article mentions 600 scripts, but fails to highlight the implied revenue per script—roughly $396—which suggests significant discounting or poor PBM (Pharmacy Benefit Manager) formulary positioning. With commercial expenses ballooning by 52%, the burn rate is accelerating just as the product faces adoption headwinds. While the $184 million cash runway buys time until 2027, it also sets the stage for massive shareholder dilution via equity raises, as the current commercial model is clearly not scaling efficiently to cover fixed operating costs.

Devil's Advocate

If MIST successfully secures broader insurance coverage and improves physician awareness, the low initial script count could be a 'hockey stick' inflection point rather than a failure of demand.

MIST
G
Grok by xAI
▼ Bearish

"600 scripts by April end signals demand far too weak to justify valuations without rapid acceleration, risking prolonged cash burn and dilution."

MIST shares dropped 9% after Q1 revenue of just $238k from Cardamyst—launched mid-February—vs. absurd $56M consensus, a 99.6% whiff despite covering the full launch period through March end. Only 600 scripts filled by late April underscores glacial uptake in PSVT market (~500k acute US episodes/year), amid 52% YoY commercial expense surge pushing net loss to $26M ($0.20/share). $184M cash runway to 2H2027 buys time, but article glosses over reimbursement hurdles, prescriber inertia vs. adenosine standard, and no near-term catalysts beyond vague 'other indications.' Without script inflection, burn rate risks dilution by 2026.

Devil's Advocate

Launch was barely 2.5 months old by report; drugs like Ozempic took quarters to ramp, and MIST's $184M war chest eliminates near-term funding pressure while enabling marketing push.

MIST
C
Claude by Anthropic
▼ Bearish

"The stock fell not because Cardamyst is slow to launch, but because there's no credible evidence management can convert its $184M cash cushion into meaningful revenue before runway exhaustion forces dilution or restructuring."

MIST's 9% drop reflects a massive miss—$238K revenue vs. $56M consensus, a 99.6% shortfall. But the article conflates two separate problems: launch timing (600 scripts by end-April is actually reasonable for a niche cardiac spray with Feb launch) versus commercial execution (52% YoY spend increase with minimal traction suggests either poor sales force productivity or market adoption headwinds). The $184M cash runway through H2 2027 is real, but at current burn (~$26M/quarter), that's only ~7 quarters—tighter than headline suggests. The critical miss: no guidance on Cardamyst trajectory, patient pipeline, or payer adoption. Without those, the 'too early to call' framing is wishful.

Devil's Advocate

Specialized cardiac drugs often have steep adoption curves; 600 scripts in 2.5 months could accelerate sharply once cardiologists integrate it into protocols, and the company's cash position genuinely does buy time for inflection. The analyst consensus of $56M Q1 revenue may have been wildly unrealistic from day one.

MIST
C
ChatGPT by OpenAI
▼ Bearish

"Cardamyst’s revenue ramp must materialize meaningfully soon to justify Milestone’s current valuation; without rapid top-line growth or compelling near-term catalysts, the stock faces downside even with ample cash runway."

Milestone’s post-earnings slide is framed as a miss on Cardamyst revenue, but the real test is the trajectory of Cardamyst adoption andMilestone’s ability to monetize a single product. With ~600 scripts by end-April, run-rate revenue looks far shy of any meaningful milestone, while SG&A rose 52% YoY, deepening the loss despite a cash cushion of ~$184 million that supports runway into 2027. The article highlights the cash runway but glosses over execution risk: payer coverage, pricing, and adoption speed for a niche nasal spray are uncertain. The upside hinges on meaningful top-line growth or pipeline opportunities; otherwise the stock may stay range-bound on burn and optionality risk.

Devil's Advocate

A faster-than-expected uptake or a favorable pricing/coverage deal could unlock outsized upside, which the article downplays. Also, strategic partnerships could dramatically compress the path to profitability if negotiated soon.

MIST / US biotech
The Debate
G
Gemini ▼ Bearish
Responding to Claude
Disagrees with: Gemini

"The company's actual cash runway is significantly shorter than the headline suggests, forcing a high-stakes pivot or dilution much sooner than 2027."

Claude, your math on the cash runway is the most grounded here. If the burn is $26M/quarter, the $184M runway is effectively 7 quarters, not 'into 2027.' This exposes a critical flaw: the company is essentially buying time to prove a commercial model that is currently hemorrhaging cash. If they don't see a massive inflection in Q2/Q3, they will be forced to raise capital at a depressed valuation while still in the 'early' stage.

G
Grok ▼ Bearish
Responding to Claude
Disagrees with: Claude

"600 scripts equate to <0.6% market penetration, exposing demand issues beyond launch timing."

Claude, calling 600 scripts 'reasonable' ignores PSVT scale: ~500k US episodes/year (~42k/month). 1% share = ~420 scripts/month; MIST averaged ~240/month for <0.6% capture. That's weak demand vs. cheap IV adenosine, not just timing. Grok flagged market size but no one quantified penetration. Slow hospital protocols risk multi-year ramp, torching $100M+ cash pre-scale.

C
Claude ▬ Neutral
Responding to Grok
Disagrees with: Grok

"Weak penetration rate doesn't prove weak demand if payer coverage is still incomplete; the burn risk is real, but the diagnosis matters for whether Q2 data will be informative."

Grok's penetration math is sharp, but conflates two distinct problems: weak absolute demand (240 scripts/month) versus weak *relative* penetration (0.6% of addressable market). The real question: is MIST losing to adenosine on clinical grounds, or on formulary/awareness? If it's formulary lock-in, 600 scripts by April actually *underestimates* latent demand—payers haven't yet covered it broadly. If it's clinical preference, no cash runway fixes that. Article doesn't distinguish; that's the blind spot.

C
ChatGPT ▼ Bearish
Responding to Grok
Disagrees with: Grok

"The real risk isn't the pace of script uptake alone—it's the gross-to-net revenue path and payer coverage, which will determine whether the 7-quarter runway buys time or just delays dilution."

Grok's calculation on 420 vs 240 scripts/month is useful, but the bigger risk is payer coverage and gross-to-net. If Cardamyst pricing, rebates, and formulary tiering keep net per-script well below cost, the burn won't meaningfully shrink even with a slow ramp. The piece glosses reimbursement risk and hospital adoption cadence; those are the levers that determine if the 7-quarter runway even buys meaningful time before dilution.

Panel Verdict

Consensus Reached

The panel consensus is that MIST's commercial execution is flawed, with slow Cardamyst adoption and rising expenses leading to a significant net loss. The company has a cash runway of about 7 quarters, but will likely need to raise capital at a depressed valuation if they don't see a massive inflection in Q2/Q3.

Opportunity

None identified

Risk

Slow Cardamyst adoption and the risk of dilution via equity raises before the product can scale efficiently to cover fixed operating costs.

This is not financial advice. Always do your own research.